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Abstract
Background: Pulp necrosis is one of the main complications of dental trauma. When it happens on an immature
tooth, pulp necrosis implies a lack of root maturation and apical closure. A therapy called apexification is required
to induce the formation of a calcified apical barrier allowing a permanent and hermetic root filling. The aim of this
prospective randomized clinical trial is to compare Mineral Trioxide Aggregate(MTA)with Calcium Hydroxide(CH)as
materials used to induce root-end closure in necrotic permanent immature incisors.
Methods/Design: This study, promoted by AP-HP, was approved by the ethics committee(CPP Paris Ile de France
IV). 34 children aged from 6 to 18 years and presenting a non-vital permanent incisor are selected. Prior to
treatment, an appropriate written consent has to be obtained from both parents and from children. Patients are
then randomly assigned to either the MTA(experimental)or CH(control)groups. Recalls are performed after 3, 6 and
12 months to determine the presence or absence of a calcified apical barrier through the use of clinical and
radiographic exams. Additional criteria such as clinical symptoms, apical radiolucencies, periapical index(PAI)are also
noted.
Trial registration: ClinicalTrials.gov no. NCT00472173 (First inclusion: May 10, 2007; Last inclusion: April 23, 2009;
study completed: April 15, 2010)
Background
Dental injuries are very common in children between six
and nine years old. A serious complication of these trau-
mas is the pulp necrosis whose prevalence varies with
the type of traumatism from 1-6% for crown fractures
to nearly 100% for intrusions [1]. The pulp necrosis of
permanent immature teeth implies the interruption of
the root formation and apical closure. It is then neces-
sary to implement a therapy, called apexification to
induce a hard calcific barrier at the apical end of the
root, to achieve the definitive root canal filling. For a
long time, calcium hydroxide was the only material used
in the apexification procedure: The treatment consists
in repeated stimulations with calcium hydroxide, over a
six to eighteen months’ period, until the apical closure
is achieved [2]. Many studies in the literature report
inconveniences linked to that procedure:
- The treatment involves numerous visits over a pro-
longed period and the patients may therefore fail to
attend their appointments. It may also lead to a loss of
temporary dressings and a re-infection of teeth. It is
moreover impossible to perform a permanent restora-
tion [3].
- In retrospective studies, cervical root fractures were
said to occur on teeth during or following treatment
with calcium hydroxide due to thin dentinal walls in
immature teeth as well as to weakened dental structure
induced by calcium hydroxide [4-7].
To avoid these inconveniences, the use of new materi-
als potentially inducing mineralisation such as Mineral
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the existing literature was done to determine if MTA
could be considered an alternative to calcium hydroxide
in apexification of permanent immature teeth. The ana-
lysis of in vitro and animal studies reveals different
properties of MTA which seem interesting as regards
apexification, offering good sealing ability [9-15], antimi-
crobial properties [11,16,17], a setting ability uninhibited
by blood or water [11,18], biocompatibility, low cyto-
toxicity [19-22], non-resorbable nature [11,23] and also
an effect on the induction of odontoblasts and of a hard
barrier [11,24-30]. The MTA(Proroot
® MTA, Dentsply
Maillefer France)is a medical device benefiting of EC
marking. It is a powder mixed with sterile water to
obtain a dental filling cement, used routinely for differ-
ent clinical protocols in odontology. All clinical cases
reported in the literature show, after a period of about
six to twelve months, an absence of pathological clinical
signs, the healing of a possible periapical lesion and the
development of an apical closure [31-40]. However, the
absence of a clinical comparative prospective study is to
be deplored and we do not have the benefit of hindsight.
That is why the implementation of a randomized clinical
study in a public hospital is interesting to compare cal-




- The main objective of this study is to test the ability of
MTA, used as a root-end filling material, to induce a
hard calcific barrier to seal hermetically non vital imma-
ture anterior permanent teeth with open apices over a 6
month’s period.
MTA is a filling material allowing the creation of an
artificial apical barrier-the MTA apical plug-but it is not
good enough. The advantage of MTA is to induce a
very close formation of mineralized tissue which is
going to coat gradually the entire apex adhering to the
MTA and the root walls. The interest of MTA is not
only to create an immediate apical sealing(mechanical
barrier)to induce a successful healing but also to pro-
mote the root-end growth or apexification, and finally
the “bio-integration” of the non-vital immature perma-
nent tooth.
- Secondary objectives:
￿ To assess the presence or absence of periapical
radioluciency indicating the emergence or persis-
tence of an apical periodontitis
￿ To compare the time required to obtain the clini-
cal healing and the disappearance of clinical symp-
toms with the two materials: MTA and Calcium
Hydroxide, when symptoms such as pain, swelling,
sinus tract, abscess or abnormal mobility are present
at the beginning of the study.
Hypothesis
In children with pulp necrosis of a permanent immature
incisor, MTA is not better than calcium hydroxide in
the rates of a calcified apical barrier, but MTA is more
valuable to achieve a biologic periapical barrier before 6
months.
Research type
Randomized controlled trial(RCT), monocentric, open-
labeled, superiority trial
Subjects
The studied sample is composed of 34 children and
teenagers, aged from 6 to 18 years presenting a pulp
necrosis of a permanent immature incisor. The root
maturation is normally completed 3 or 4 years after the
tooth eruption, that is to say around the age of 9 or 10
years as far as incisors are concerned. However some
teenagers present teeth damaged by a trauma before
their maturation was achieved. That is the reason why
such patients are included in the study when those trau-
mas were not or unsuccessfully dealt with. The number
of patients needed for this study was calculated prior to
investigation with the hypothesis of a higher successful
apexification rate in the MTA group compared to the
control CH group. The anticipated success rates at 6
months were 5% in the CH group and 50% in the MTA
group; Given these hypotheses, it was necessary to
include 15 patients in each group that is to say a total
of 30 patients to have a 80% statistical power(with a a
risk of 5%), to compare the proportion of apical closure
at 6 months with a Chi-2 test(two sided). Taking into
account an anticipated dropout of 5%, it was decided to
i n c l u d e3 4p a t i e n t s .S a m p l es i z ec a l c u l a t i o n sw e r ec o m -
puted with nQuery Advisor
® 6.01. For ethical reasons,
the sample size was limited while remaining compatible
with the ability to obtain a significant difference between
the two materials. The case reports published in the lit-
erature show a periapical repair within the first 6
months whereas the apical bridging induced with cal-
cium hydroxide is more often obtained after a period of
6 to 18 months. That is why we hypothesized that after
a period of 6 months, at least half of the MTA cases
would be a success for the main objective as opposed to
a minimal percentage for the calcium hydroxide group.
Inclusion criteria
I1-Patient presenting a non-vital permanent imma-
ture incisor for which an apexification treatment is
indicated
I2-Aged 6-18 years
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E1.1-History of uncontrolled diabetes
E1.2-Immunosuppression
E1.3-Severe asthma
E1.4-Chronic systemic disease if a treatment is
required
E1.5-Eating disorder(anorexia, bulimia, malnutrition,
...)
E2-Oral pathology: Periodontal disease
E3-Corticosteroid treatment during the last 3 months
E4-Non-affiliation to a social security scheme
Suspension criteria
S1-Poor compliance
S2-New trauma or new complication
S3-Intercurrent illness requiring discontinuation of
the trial
When patients are lost sight of, observations must be
n o t e dd o w ni nt h eC R Fu n t i lt h el a s te f f e c t e dv i s i t .T h e
investigators will do their best to contact the patient
and find out why the patient ceased being in the trial.
Randomization
Participants are assigned in a treatment group by an
independent statistician. Random numbers were ran-
domly determined via a block randomization with a 1:1
ratio and blocks size of 4. The block size was concealed
from all researchers. The randomization of the trial is
centralized and conducted by an external authority: the
Unity of Clinical Research(UCR). After the informed
consent form is obtained, the investigator sends a ran-
domization request fax to the UCR that sends back the
random number according to the random sequence list.
The latter fax is also sent to the hospital pharmacy that
delivers the products necessary to the study.
Design of the study-Interventions
For each patient the protocol is composed of 7 sessions
(Table 1). The follow-up takes place over a 12 months’
period. Day 0 is considered as the day of the first treat-
ment session.
1. Day 0-14/Day 0: Inclusion and selection visit
Diagnosis of pulp necrosis, clinical and radiographic
exams
Written informed consent is obtained from both par-
ents and from the child.
2. Day 0: Calcium hydroxide canal conditioning
regardless of the treatment group
This treatment is performed under local anesthesia
with Articaïne with adrenalin 1/200000(Septanest, Sep-
todont, France), after placement of a rubber dam. After
preparing an access cavity and establishing the working
length by taking a radiograph with a file inserted into
the root canal within 1 mm of the radiographic apex,
the canal is cleaned by irrigation with 3% sodium hypo-
chlorite(Parcan, Septodont, France)and the use of man-
ual files. The cleaning and shaping are realized with files
with a very light parietal action to avoid the canal
widening and the weakening of the root walls. Above
all, it consists in removing the pulp remnants. The most
important thing is to observe the vacuity and cleanliness
of the canal using operative microscopy. Considering
the root immaturity, it is actually a cleaning and desin-
fection without shaping. Then the canal is dried with
paper point and can be filled with calcium hydroxide.
Calcium hydroxide paste is prepared by mixing the cal-
cium hydroxide powder(obtained from the hospital
pharmacy)with an anaesthetic solution(Scandicaïne, Sep-
todont, Saint Maur des Fossés, France). A plug of cal-
cium hydroxide is deposed in the canal and condensed
to the apical end of the root with a plugger. Other
applications of calcium hydroxide are realized, until
complete canal filling. The excess moisture is dried
between each input with sterile paper points. The intra-
canal dressing quality is checked with a radiograph. The
access cavity is temporarily sealed with a resin modified
glass ionomer cement(Fuji II LC, GC, Bonneuil sur
Marne, France). This calcium hydroxide canal condi-
tioning is performed for all patients to allow the com-
plete disinfection already obtained thanks to irrigation
with sodium hypochlorite and the use of manual files, to
control acute symptoms and to allow further treatments.
3. Day0+15: MTA apical filling for the testing group/
calcium hydroxide renewal for the control group
This session starts with a local anesthesia, the place-
ment of a rubber dam and the removal of all the cal-
cium hydroxide. For this procedure, the canal has to be
cleaned by irrigation and the use of ultrasonic files to
remove all the calcium hydroxide. The use of EDTA
allows a more complete elimination but due to these
teeth immaturity the EDTA is not recommended. Then,
the treatment differs among the treatment group:
For the MTA group, a MTA plug is placed into the
canal with a root canal messing gun and condensed to
the apical end of the root with a plugger to create a 4
mm apical plug of MTA. The pipe of the MTA gun is
adjusted for the piston to deliver a 3 mm plug. Coarse
paper points are used upside down to perfect the MTA
adaptation to the apical walls. A radiographic control
allows the practitioner to verify the good placement of
MTA. A paper point moistened with sterile water is
placed in the canal to produce an ambient humidity for
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is filled with conventional glass ionomer cement(Fuji IX,
GC, Bonneuil sur Marne, France).
- For the CH group, the complete filling with calcium
hydroxide is obtained as the first treatment session.
4. Day 0+21: Control for the CH group/complete fill-
ing with gutta-percha for the MTA group. The hardness
of the MTA is checked with an endodontic file and the
root canal filling with gutta-percha can be realized in
contact with MTA. This filling is realized with the
Schilder’s technique: warm gutta-percha compacted with
the Touch’n Heat(SybronEndo, Henry Schein, Alfort-
ville, France). The access cavity is then sealed with a
composite resin.
5. 3 months: clinical and radiographic control for all
patients, and calcium hydroxide renewal for CH group
patients.
6. 6 months: clinical and radiographic control for all
patients and for CH group patients, calcium hydroxide
renewal or complete root filling with gutta-percha if an
apical barrier is present.
7. 12 months: clinical and radiographic control
For the teeth of CH group not filled with gutta-
percha, the following treatment is realized outside study.
All the treatment sessions are realized in the same
dental office, under local anesthesia, after placement of
a rubber dam and with optical aids, by the same two
operators, one assistant and the other alternately.
The X-Rays of each patient are standardized so that
they can be compared. When each patient has his first
X-Ray taken, the patient is asked to bite into a piece of
silicone which enables the operator to put the film
holder in the same position at each session(Figure 1a, b,
c). Thus the radiographs can be reproducible.(Figures
2a, b, c)
Evaluation criteria
The assessment criteria are both clinical and radio-
graphic(Table 2).
Assessment with the patient at each session
First, the evaluation is realized at each session by the
investigators-operators, who assess the presence or
absence of clinical symptoms such as pain, abnormal
mobility, swelling, sinus tract, abcess and percussion
tenderness. Radiographic exams allow the evaluation of
the main success criterion, the presence or absence of a
calcified apical barrier as well as the presence of a radi-
oluscent image and the form and thickness of the apical
barrier. These investigators can compare all the patient’s
radiographs.
All these data are immediately entered in the CRF.
Anonymous evaluation at the end of the study
Two independent investigators will study all the anon-
ymized X-Rays. This assessment will be done without
the investigators having any information about the
treated patients, their treatment or the nature of the ×
rays(preoperative, postoperative, after 3, 6 or 12
months). If the conclusions of the two investigators
diverge, a third one will settle the matter. These anon-
ymous data will be sent to the UCR that will then
remove the anonymity before sending the service sta-
tistics for analysis.
Expected benefits
The dental root canal can be hermetically filled immedi-
ately after the MTA hardens thus reducing the number
of sessions and the length of the treatment.
Predictable risks
Many in Vitro and In Vivo studies on MTA biocompat-
ibility have been realized [21,25,26,41]. Ribeiro et al.
Table 1 Study protocol for each included patient
Sessions 1 2 3 4 5 6 7
Timing D-15 to
D0
D0 D + 15 D+21 3 months 6 months 12
months
Written informed consent X
Inclusion and exclusion criteria X
Diagnosis of immature tooth pulp
necrosis
X
Clinical exam: symptoms XX X X X X X
Radiographic exam XX X X X X X
Calcium hydroxide filling or renewal X X(CH
group)
X(CH group-no barrier) X(CH group-no barrier)
Apical filling with MTA X(MTA
group)
Complete filling with gutta-percha X(MTA
group)
X(CH group and apical
barrier)
X(CH group and apical
barrier)
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harmful effects of MTA [42]. Souza et al.(2006)carried
out a study about the toxicity of 6 dental biomaterials
and proved MTA was the least harmful of all [43]. This
protocol does not involve any risks of serious side-
effects entailed by the treatment.
Undesirable events
Any adverse event observed during the study or the fol-
low-up has to be reported in the CRF. Some information
including occurrence time, duration, severity and treat-
ment of this undesirable event should be noted as well.
The relationship between adverse event and the apexifi-
cation treatment has to be assessed(biological and
mechanical failure).
Monitoring and inspection
Monitor should regularly visit the dental office to con-
trol the process of study and the CRF, check storage of
investigational dental products and record of data.
Figure 1 Device used to realize reproducible radiographs at each session. The patient is asked to bite into a piece of silicone, which
enables us to put the film holder and so the radiograph in the same position at each session. 1a: piece of silicone. 1b: film holder. 1c:
Radiograph.
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This study has been promoted by AP-HP(Paris Public
Hospital)and approved by the ethics committee(CPP
Paris Ile de France IV)and other French institutions:
- CNIL: French data protection watchdog
- AFSSAPS: the French Medecine and healthcare pro-
ducts regulatory agency, equivalent of the Food and
Drug Administration in the United States.
Informed consent form(ICF)has been reviewed and
approved by the ethics committee before study. Infor-
mation about the protocol should be given to children
and their parents both orally and in writing in an easily
understandable language. The ICF must be dated and
signed by the child and the parents(or representatives),
and 3 copies must be made to be kept by the partici-
pants, the investigators and the UCR(15 years).
All information about the participants must be kept
confidential.
Statistical analysis
All the analyses followed an intention-to-treat principle
and will be conducted to compare the efficacy of MTA
with CH to induce root-end closure in necrotic perma-
nent immature incisors at 6 months. Secondary efficacy
endpoints are apical radiolucencies and PeriApical Index
(PAI = 1, 2: healthy or PAI = 3, 4, 5: pathological)
Primary endpoints, ie, proportions of patients with an
apical barrier close at 6 months will be compared
between treatment groups with the Fisher’se x a c tt e s t ,
such as with the secondary endpoints.
To handle missing data on the primary endpoint, sev-
eral procedures will be used where the missing values
will be either dropped-out or replaced according to 3
simple imputation methods as follows:
Figure 2 The reproducibility of the radiographs taken at each session allowing us to compare them. 2a: Radiograph taken during the
inclusion session. 2b: Radiograph taken at the 6th month session. 2c: radiograph taken at the 12th month session.
Table 2 Data reported in the CRF
















Periodontal ligament enlargement XXXXXXX
Presence of an apical barrier X XXX
Radioluscent image XXXXXXX
PAI XXXXXXX
Form of the apical barrier XXX
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dropped out.
- Worst-case analysis: missing values are considered
as a failure(apical barrier not closed at 6 months)in
MTA group and as a success in CH group.
- Best-case analysis: missing values are considered as
a success(apical barrier closed at 6 months)in MTA
group and as a failure in CH group.
- Last Observation Carried Forward(LOCF):previous
diagnostic is used to replace missing values.
The assessment of concordance between the two inde-
pendent investigators about the closure of apical barrier
at baseline, months 3, months 6 and months 12 will be
given with the Kappa coefficient and the 95% confidence
interval.
Analyses will be performed by two statisticians of
Biostatistics and Epidemiology unit of Cochin Hospital
(Paris)using SAS 9.1(SAS Institute Inc, Cary, North Car-
olina); tests will be 2-sided, and 0.05 will be used as the
threshold for statistical significance.
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